{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:02:03Z","timestamp":1791075723090,"version":"4.1.0"},"reference-count":41,"publisher":"American Diabetes Association","issue":"11","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,11,1]]},"abstract":"<jats:p>Islet amyloid has been suggested to be an important link between insulin resistance and \u03b2-cell dysfunction in type 2 diabetes. To investigate the prevalence and clinicopathological characteristics of islet amyloid, we examined consecutive autopsies of 235 Chinese patients with type 2 diabetes and 533 nondiabetic subjects. Islet amyloid deposits were identified using Congo red staining and quantitated by image analysis. We found that 3.0% of the nondiabetic subjects versus 39.6% of the diabetic patients displayed islet amyloid (P &amp;lt; 0.001). In diabetic patients, the amyloid deposits occupied a mean islet area of 36.2%, which was positively associated with BMI, blood pressure, and glycemic control. Pancreatic fibrosis and fat infiltration were more frequently found in diabetic patients with islet amyloid than those without islet amyloid, whereas pancreatic arteriosclerosis was identified in all diabetic patients. These findings suggest that islet amyloid deposits reflect greater insulin resistance and islet failure in a subgroup of type 2 diabetic patients. Islet failure may also have been exacerbated by fat infiltration, fibrosis, and arteriosclerosis. Optimal blood pressure and metabolic control may reduce these pathological changes and help preserve islet cell mass.\u2003<\/jats:p>","DOI":"10.2337\/diabetes.52.11.2759","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T19:04:22Z","timestamp":1173207862000},"page":"2759-2766","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":112,"title":["Prevalence and Clinicopathological Characteristics of Islet Amyloid in Chinese Patients With Type 2 Diabetes"],"prefix":"10.2337","volume":"52","author":[{"given":"Hai-Lu","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics, The Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernand M.M.","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Anatomical and Cellular Pathology, The Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.Y.","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Rong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana C.N.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031208233666900_R1","doi-asserted-by":"crossref","unstructured":"Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest\u2008104:787\u2013794,1999","DOI":"10.1172\/JCI7231"},{"key":"2022031208233666900_R2","doi-asserted-by":"crossref","unstructured":"Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev\u200819:477\u2013490,1998","DOI":"10.1210\/edrv.19.4.0336"},{"key":"2022031208233666900_R3","doi-asserted-by":"crossref","unstructured":"Taylor SI, Accili D, Imai Y: Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?Diabetes\u200843:735\u2013740,1994","DOI":"10.2337\/diab.43.6.735"},{"key":"2022031208233666900_R4","doi-asserted-by":"crossref","unstructured":"Hoppener JW, Ahren B, Lips CJ: Islet amyloid and type 2 diabetes mellitus. N Engl J Med\u2008343:411\u2013419,2000","DOI":"10.1056\/NEJM200008103430607"},{"key":"2022031208233666900_R5","doi-asserted-by":"crossref","unstructured":"Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes\u200848:241\u2013253,1999","DOI":"10.2337\/diabetes.48.2.241"},{"key":"2022031208233666900_R6","doi-asserted-by":"crossref","unstructured":"de Koning EJ, Bodkin NL, Hansen BC, Clark A: Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia\u200836:378\u2013384,1993","DOI":"10.1007\/BF00402271"},{"key":"2022031208233666900_R7","doi-asserted-by":"crossref","unstructured":"Clark A, Jones LC, de Koning E, Hansen BC, Matthews DR: Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function?Diabetes\u200850 (Suppl. 1):S169\u2013S171,2001","DOI":"10.2337\/diabetes.50.2007.S169"},{"key":"2022031208233666900_R8","doi-asserted-by":"crossref","unstructured":"Maloy AL, Longnecker DS, Greenberg ER: The relation of islet amyloid to the clinical type of diabetes. Hum Pathol\u200812:917\u2013922,1981","DOI":"10.1016\/S0046-8177(81)80197-9"},{"key":"2022031208233666900_R9","doi-asserted-by":"crossref","unstructured":"Westermark P: Amyloid and polypeptide hormones. What is their inter-relationship?Amyloid\u20081:47\u201360,1994","DOI":"10.3109\/13506129409148624"},{"key":"2022031208233666900_R10","doi-asserted-by":"crossref","unstructured":"Clark A, Charge SB, Badman MK, de Koning EJ: Islet amyloid in type 2 (non-insulin-dependent) diabetes. APMIS\u2008104:12\u201318,1996","DOI":"10.1111\/j.1699-0463.1996.tb00680.x"},{"key":"2022031208233666900_R11","unstructured":"Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res\u20089:151\u2013159,1988"},{"key":"2022031208233666900_R12","doi-asserted-by":"crossref","unstructured":"Bell ET: Hyalinization of the islets of Langerhans in diabetes mellitus. Diabetes\u20081:341\u2013344,1952","DOI":"10.2337\/diab.1.5.341"},{"key":"2022031208233666900_R13","doi-asserted-by":"crossref","unstructured":"Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A\u200887:5036\u20135040,1990","DOI":"10.1073\/pnas.87.13.5036"},{"key":"2022031208233666900_R14","doi-asserted-by":"crossref","unstructured":"Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia\u200833:285\u2013289,1990","DOI":"10.1007\/BF00403322"},{"key":"2022031208233666900_R15","unstructured":"Vishwanathan KA, Bazaz-Malik G, Dandekar J, Vaishnava H: A qualitative and quantitative histological study of the islets of Langerhans in diabetes mellitus. Indian J Med Sci\u200826:807\u2013812,1972"},{"key":"2022031208233666900_R16","doi-asserted-by":"crossref","unstructured":"Saito K, Yaginuma N, Takahashi T: Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J Exp Med\u2008129:273\u2013283,1979","DOI":"10.1620\/tjem.129.273"},{"key":"2022031208233666900_R17","doi-asserted-by":"crossref","unstructured":"Ohsawa H, Kanatsuka A, Mizuno Y, Tokuyama Y, Takada K, Mikata A, Makino H, Yoshida S: Islet amyloid polypeptide-derived amyloid deposition increases along with the duration of type 2 diabetes mellitus. Diabetes Res Clin Pract\u200815:17\u201321,1992","DOI":"10.1016\/0168-8227(92)90062-V"},{"key":"2022031208233666900_R18","doi-asserted-by":"crossref","unstructured":"Rahier J, Goebbels RM, Henquin JC: Cellular composition of the human diabetic pancreas. Diabetologia\u200824:366\u2013371,1983","DOI":"10.1007\/BF00251826"},{"key":"2022031208233666900_R19","doi-asserted-by":"crossref","unstructured":"Pancreatic abnormalities in type 2 diabetes mellitus (Editorial). Lancet\u2008ii:1497\u20131498,1987","DOI":"10.1016\/S0140-6736(87)92626-2"},{"key":"2022031208233666900_R20","doi-asserted-by":"crossref","unstructured":"Clark A, de Koning EJ, Hattersley AT, Hansen BC, Yajnik CS, Poulton J: Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res Clin Pract\u200828:S39\u2212S47,1995","DOI":"10.1016\/0168-8227(95)01075-O"},{"key":"2022031208233666900_R21","unstructured":"International Obesity Task Forces: The Asia-Pacific Prospective: Redefining Obesity and Its Treatment. Sydney, Health Communications Australia,2000, p.15\u201321"},{"key":"2022031208233666900_R22","doi-asserted-by":"crossref","unstructured":"Rocken C, Linke RP, Saeger W: Immunohistology of islet amyloid polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem series. Virchows Arch\u2008421:339\u2013344,1992","DOI":"10.1007\/BF01660981"},{"key":"2022031208233666900_R23","doi-asserted-by":"crossref","unstructured":"O\u2019Brien TD, Butler AE, Roche PC, Johnson KH, Butler PC: Islet amyloid polypeptide in human insulinomas: evidence for intracellular amyloidogenesis. Diabetes\u200843:329\u2013336,1994","DOI":"10.2337\/diabetes.43.2.329"},{"key":"2022031208233666900_R24","doi-asserted-by":"crossref","unstructured":"Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A\u200884:8628\u20138632,1987","DOI":"10.1073\/pnas.84.23.8628"},{"key":"2022031208233666900_R25","doi-asserted-by":"crossref","unstructured":"Puchtler H, Sweat F, Levine M: On the binding of Congo red by amyloid. J Histochem Cytochem\u200810:355\u2013364,1962","DOI":"10.1177\/10.3.355"},{"key":"2022031208233666900_R26","doi-asserted-by":"crossref","unstructured":"Kelenyi G: Thioflavin S fluorescent and Congo red anisotropic stainings in the histologic demonstration of amyloid. Acta Neuropathol\u20087:336\u2013348,1967","DOI":"10.1007\/BF00688089"},{"key":"2022031208233666900_R27","doi-asserted-by":"crossref","unstructured":"Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ: Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia\u200842:427\u2013434,1999","DOI":"10.1007\/s001250051175"},{"key":"2022031208233666900_R28","doi-asserted-by":"crossref","unstructured":"Hoppener JW, Nieuwenhuis MG, Vroom TM, Ahren B, Lips CJ: Role of islet amyloid in type 2 diabetes mellitus: consequence or cause?Mol Cell Endocrinol\u2008197:205\u2013212,2002","DOI":"10.1016\/S0303-7207(02)00266-6"},{"key":"2022031208233666900_R29","doi-asserted-by":"crossref","unstructured":"Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes\u200852:102\u2013110,2003","DOI":"10.2337\/diabetes.52.1.102"},{"key":"2022031208233666900_R30","unstructured":"Erlich JC, Ratner IM: Amyloidosis of the islets of Langerhans: a restudy of islet hyaline in diabetic and nondiabetic individuals. Am J Pathol\u200838:49\u201359,1961"},{"key":"2022031208233666900_R31","doi-asserted-by":"crossref","unstructured":"Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia\u200815:417\u2013421,1978","DOI":"10.1007\/BF01219652"},{"key":"2022031208233666900_R32","doi-asserted-by":"crossref","unstructured":"Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature\u2008368:756\u2013760,1994","DOI":"10.1038\/368756a0"},{"key":"2022031208233666900_R33","doi-asserted-by":"crossref","unstructured":"Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes\u200848:491\u2013498,1999","DOI":"10.2337\/diabetes.48.3.491"},{"key":"2022031208233666900_R34","doi-asserted-by":"crossref","unstructured":"Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A\u200893:7283\u20137288,1996","DOI":"10.1073\/pnas.93.14.7283"},{"key":"2022031208233666900_R35","unstructured":"Butler PC: Islet amyloid and its potential role in the pathogenesis of type 2 diabetes mellitus. In Diabetes Mellitus: A Fundamental and Clinical Text. 2nd ed. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott Williams & Wilkins,2000, p.141\u2013146"},{"key":"2022031208233666900_R36","doi-asserted-by":"crossref","unstructured":"Janciauskiene S, Ahren B: Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun\u2008267:619\u2013625,2000","DOI":"10.1006\/bbrc.1999.1989"},{"key":"2022031208233666900_R37","doi-asserted-by":"crossref","unstructured":"Pieber TR, Roitelman J, Lee Y, Luskey KL, Stein DT: Direct plasma radioimmunoassay for rat amylin-(1\u201337): concentrations with acquired and genetic obesity. Am J Physiol\u2008267:E156\u2212E164,1994","DOI":"10.1152\/ajpendo.1994.267.1.E156"},{"key":"2022031208233666900_R38","doi-asserted-by":"crossref","unstructured":"Soeller WC, Janson J, Hart SE, Parker JC, Carty MD, Stevenson RW, Kreutter DK, Butler PC: Islet amyloid-associated diabetes in obese avy\/a mice expressing human islet amyloid polypeptide. Diabetes\u200847:743\u2013750,1998","DOI":"10.2337\/diabetes.47.5.743"},{"key":"2022031208233666900_R39","doi-asserted-by":"crossref","unstructured":"Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia\u200837:188\u2013194,1994","DOI":"10.1007\/s001250050092"},{"key":"2022031208233666900_R40","doi-asserted-by":"crossref","unstructured":"Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O\u2019Connor DT: Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens\u200818:1611\u20131620,2000","DOI":"10.1097\/00004872-200018110-00012"},{"key":"2022031208233666900_R41","doi-asserted-by":"crossref","unstructured":"Kauppila LI, Hekali P, Penttila A: Postmortem pancreatic angiography in 45 subjects with non-insulin-dependent diabetes mellitus and 51 controls. Pancreas\u200816:60\u201365,1998","DOI":"10.1097\/00006676-199801000-00010"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/52\/11\/2759\/373414\/db1103002759.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/52\/11\/2759\/373414\/db1103002759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:16:24Z","timestamp":1667405784000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/52\/11\/2759\/12709\/Prevalence-and-Clinicopathological-Characteristics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.52.11.2759","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,1]]}}}